drugset

drugset / Trial / NCT06959225

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225 ↗

Phase 3 Recruiting 550 enrolled Incyte Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Timeline

Start: 2025-06-23
Primary completion: 2026-10-09
Completion: 2027-07-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Indications